Acadia
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
12830 El Camino Real Ste 400, San Diego,...Phone Number
(858) 558-2871Website
www.acadia.comRevenue
$1.1 BillionStock Symbol
ACADIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
7
1
2
2
2
1
About Acadia
Acadia Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimers disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.Explore more
Acadia Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Acadia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Acadia has recently received funding, and reach out quickly before it becomes old news!
Acadia, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Acadia is spiking on competitors!
Product Launch: Get notified when Acadia launches new products
Earning: See what the market has to say on Acadia recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Acadia
Funding: Get notified immidiatlly once Acadia has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Acadia had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Acadia is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Acadia is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Acadia.
Acadia financials insights
Gather financial insights about Acadia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2003
Share Placement
$25M
Share Placement
$3M
2007
Private Equity
$102.5M
2011
Share Placement
$15M
2019
Stock Offering
$287.5M
2020
Stock Offering
$10M
Acadia Tech Stack
A closer look at the technologies used by Acadia
See more technologies
Most Recent Scoops
Hiring Plans
Acadia has more open roles in Engineering & Technical than it has had at any time in the past 12 months.
Hiring Plans
Person-Based
Marketing Campaign
Person-Based
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Acadia News & Media
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Bank of America Global Healthcare Conference 2026 May 12, 2026 7:20 PM EDTCompany ParticipantsCatherine Owen Adams - CEO...ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference. Chief Executive Officer CatACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call May 6, 2026 4:30 PM EDTCompany ParticipantsAlbert Kildani - Senior Vice President of Investor...ACADIA Pharmaceuticals Q1 Earnings Call Highlights
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported first-quarter 2026 total revenue of $268 million, and executives said the company is maintaining its full-year outlook as it advances a pipeline led by remlifanserin in Alzheimer’s disease psychosis and trofinetide in Japan. Chief Executive Officer Cath
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Acadia
Sign Up For FreeTo access detailed company insights
Acadia Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II t... Read More
